LKFT — Lakefront Biotherapeutics NV Share Price
0.000.00%
Last trade - 00:00- €1.57bn
- -€1.41bn
- €1.11bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.48 | ||
| Price to Tang. Book | 0.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.5 | ||
| EV to EBITDA | -3.61 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.92% | ||
| Return on Equity | 16.26% | ||
| Operating Margin | 37.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 538.6 | 277.38 | 239.72 | 275.65 | 1,112.25 | 277.87 | 257.44 | 15.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +106.75 | +2179.64 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lakefront Biotherapeutics NV is a Belgium‑based company. The Company develops medicines for patients with serious diseases in areas of unmet medical need and uses deal‑making capabilities and capital to identify, acquire, and advance opportunities that create value for patients and shareholders. Its pipeline includes clinical‑stage immunology and oncology programs, such as autoimmune disease candidates and selected oncology assets, primarily advanced through partnerships and targeted development rather than in‑house cell therapy platforms. It builds a portfolio of clinical‑stage therapies intended to support existing treatment approaches and operates across oncology and immunology and inflammation programs supported by clinical proof of concept in emerging therapeutic areas.
Directors
- Onno van de Stolpe CMG (61)
- Rajesh Parekh NEC (61)
- Bart Filius PRE (50)
- Walid Abi-Saab EXB (55)
- Andre Hoekema EXB (63)
- Michele Manto EXB (48)
- Linda Higgins NED (58)
- Daniel O' Day NED (58)
- Katrine Bosley NID (52)
- Peter Guenter NID (58)
- Mary Kerr NID (60)
- Howard Rowe NID (51)
- Elisabeth Svanberg NID (61)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- July 17th, 1999
- Public Since
- May 6th, 2005
- No. of Employees
- 452
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Amsterdam
- Shares in Issue
- 65,897,071
- Address
- Generaal De Wittelaan L11 A3, MALINES (MECHELEN), 2800
- Web
- https://www.glpg.com/
- Phone
- +32 15342900
- Contact
- Sherri Spear
- Auditors
- BDO Bedrijfsrevisoren BV
Upcoming Events for LKFT
Q3 2026 Galapagos NV Earnings Release
Similar to LKFT
Vivoryon Therapeutics NV
Euronext - Amsterdam
FAQ
What is the Lakefront Biotherapeutics NV share price?
As of Today at 03:43 UTC, shares in Lakefront Biotherapeutics NV are trading at €23.78. This share price information is delayed by 15 minutes.
How has the Lakefront Biotherapeutics NV share price performed this year?
Shares in Lakefront Biotherapeutics NV last closed at €23.78 and the price had moved by +0.34% over the past 365 days. In terms of relative price strength the Lakefront Biotherapeutics NV share price has underperformed the FTSE Global All Cap Index by -11.41% over the past year.
What are the analyst and broker recommendations for Lakefront Biotherapeutics NV?
The overall consensus recommendation for Lakefront Biotherapeutics NV is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Lakefront Biotherapeutics NV dividend yield?
Lakefront Biotherapeutics NV does not currently pay a dividend.
Does Lakefront Biotherapeutics NV pay a dividend?
Lakefront Biotherapeutics NV does not currently pay a dividend.
When does Lakefront Biotherapeutics NV next pay dividends?
Lakefront Biotherapeutics NV does not currently pay a dividend.
How do I buy Lakefront Biotherapeutics NV shares?
To buy shares in Lakefront Biotherapeutics NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lakefront Biotherapeutics NV?
As of the previous close price of €23.78, shares in Lakefront Biotherapeutics NV had a market capitalisation of €1.57bn.
Where are Lakefront Biotherapeutics NV shares listed?
Here are the trading details for Lakefront Biotherapeutics NV:
- Country of listing: Netherlands
- Exchange: AEX
- Ticker Symbol: LKFT
What kind of share is Lakefront Biotherapeutics NV?
Based on an overall assessment of its quality, value and momentum Lakefront Biotherapeutics NV is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lakefront Biotherapeutics NV share price forecast for 2026?
The analyst consensus target price for shares in Lakefront Biotherapeutics NV is €29.60. That is 24.47% above the last closing price of €23.78.
Analysts covering Lakefront Biotherapeutics NV currently have a consensus Earnings Per Share (EPS) forecast of -€2.29 for the next financial year.
Find out moreWhat is the trend in the Lakefront Biotherapeutics NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lakefront Biotherapeutics NV. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -19.18%.
As of the last closing price of €23.78, shares in Lakefront Biotherapeutics NV were trading -13.33% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lakefront Biotherapeutics NV PE Ratio?
The Lakefront Biotherapeutics NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €23.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lakefront Biotherapeutics NV?
Lakefront Biotherapeutics NV's management team is headed by:
- Onno van de Stolpe - CMG
- Rajesh Parekh - NEC
- Bart Filius - PRE
- Walid Abi-Saab - EXB
- Andre Hoekema - EXB
- Michele Manto - EXB
- Linda Higgins - NED
- Daniel O' Day - NED
- Katrine Bosley - NID
- Peter Guenter - NID
- Mary Kerr - NID
- Howard Rowe - NID
- Elisabeth Svanberg - NID